2 hours Ago By Defense World Staff
Marotta Asset Management reduced its stake in AstraZeneca PLC ( NASDAQ:AZN – Free Report ) by 1.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,998 shares of the company’s stock after selling 187 shares during the period.
Marotta Asset Management’s holdings in AstraZeneca were worth $1,013,000 at the end of the most recent reporting period. Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Price T Rowe Associates Inc.
MD raised its holdings in shares of AstraZeneca by 17.2% in the 1st quarter. Price T Rowe Associates Inc.
MD now owns 61,271,974 shares of the company’s stock valued at $4,151,177,000 after purchasing an additional 9,002,450 shares in the last quarter. Fisher Asset Management LLC raised its stake in AstraZeneca by 2.2% in the fourth quarter.
Fisher Asset Management LLC now owns 9,376,193 shares of the company’s stock valued at $631,487,000 after buying an additional 205,185 shares in the last quarter. Capital World Investors lifted its holdings in AstraZeneca by 0.3% during the 1st quarter.
Capital World Investors now owns 9,365,676 shares of the company’s stock worth $634,525,000 after buying an additional 29,497 shares during the last quarter. Putnam Investments LLC boosted its position in shares of AstraZeneca by 4.5% during the 4th quarter.
Putnam Investments LLC now owns 7,729,834 shares of the company’s stock worth $520,604,000 after acquiring an additional 333,310 shares in the last quarter. Finally, Envestnet Asset Management Inc. increased its holdings in shares of AstraZeneca by 16.
7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 3,417,933 shares of the company’s stock valued at $266,565,000 after acquiring an additional 488,644 shares during the last quarter.
20.35% of the stock is currently owned by hedge funds and other institutional investors. Analysts Set New Price Targets Several equities research analysts recently commented on the stock.
Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a research report on Friday, September 13th. Citigroup raised AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th.
Barclays upgraded AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. Finally, TD Cowen increased their price objective on AstraZeneca from $90.00 to $95.
00 and gave the company a “buy” rating in a report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $89.
75. AstraZeneca Trading Down 2.1 % Shares of AZN stock opened at $77.
93 on Friday. The stock has a market cap of $241.63 billion, a P/E ratio of 38.
20, a P/E/G ratio of 1.50 and a beta of 0.46.
The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.
69. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.
68. The business has a fifty day simple moving average of $81.63 and a 200-day simple moving average of $77.
28. AstraZeneca ( NASDAQ:AZN – Get Free Report ) last released its quarterly earnings results on Thursday, July 25th. The company reported $0.
99 EPS for the quarter, beating the consensus estimate of $0.98 by $0.01.
AstraZeneca had a net margin of 13.11% and a return on equity of 29.34%.
The business had revenue of $12.45 billion for the quarter, compared to analyst estimates of $12.62 billion.
During the same period in the prior year, the business earned $1.08 earnings per share. The company’s quarterly revenue was up 9.
1% on a year-over-year basis. On average, analysts forecast that AstraZeneca PLC will post 4.07 earnings per share for the current fiscal year.
AstraZeneca Cuts Dividend The company also recently announced a Semi-Annual dividend, which was paid on Monday, September 9th. Shareholders of record on Friday, August 9th were paid a $0.49 dividend.
The ex-dividend date of this dividend was Friday, August 9th. This represents a yield of 1.8%.
AstraZeneca’s payout ratio is currently 48.04%. AstraZeneca Profile ( Free Report ) AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Featured Stories Five stocks we like better than AstraZeneca TSX Venture Exchange (Formerly Canadian Venture Exchange) When Is the Best Time to Invest in Mutual Funds? Trading Stocks: RSI and Why it’s Useful Is NVIDIA Stock in a Correction or Consolidation? Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness 3 Oversold Stocks with Big RSI Rebound Potential Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter .
.
